[go: up one dir, main page]

JPH07505398A - 良性前立腺肥大症の治療用組成物および方法 - Google Patents

良性前立腺肥大症の治療用組成物および方法

Info

Publication number
JPH07505398A
JPH07505398A JP5517741A JP51774193A JPH07505398A JP H07505398 A JPH07505398 A JP H07505398A JP 5517741 A JP5517741 A JP 5517741A JP 51774193 A JP51774193 A JP 51774193A JP H07505398 A JPH07505398 A JP H07505398A
Authority
JP
Japan
Prior art keywords
alpha
compounds
steroid
compound
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5517741A
Other languages
English (en)
Japanese (ja)
Inventor
ヒーブル，ジャコブ・ポール
メトカルフ，ブライアン・ウォルター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JPH07505398A publication Critical patent/JPH07505398A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP5517741A 1992-04-02 1993-04-02 良性前立腺肥大症の治療用組成物および方法 Pending JPH07505398A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86211792A 1992-04-02 1992-04-02
US862,117 1992-04-02
US99779292A 1992-12-29 1992-12-29
US997,792 1992-12-29
PCT/US1993/003145 WO1993019758A1 (fr) 1992-04-02 1993-04-02 Compositions et procedes permettant de traiter l'hypertrophie prostatique benigne

Publications (1)

Publication Number Publication Date
JPH07505398A true JPH07505398A (ja) 1995-06-15

Family

ID=27127672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5517741A Pending JPH07505398A (ja) 1992-04-02 1993-04-02 良性前立腺肥大症の治療用組成物および方法

Country Status (8)

Country Link
EP (1) EP0633781A4 (fr)
JP (1) JPH07505398A (fr)
KR (1) KR950700746A (fr)
AU (1) AU668157B2 (fr)
CA (1) CA2133440A1 (fr)
MX (1) MX9301939A (fr)
NZ (1) NZ251658A (fr)
WO (1) WO1993019758A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
EP0717618B1 (fr) * 1993-09-03 2002-11-06 Smithkline Beecham Corporation Formulation stabilisee pour comprimes
CA2187767A1 (fr) * 1994-04-14 1995-10-26 Joel R. Huff Antagonistes du recepteur adrenergique alpha1c
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US4963547A (en) * 1988-06-01 1990-10-16 Smithkline Beecham Corporation Alpha-andrenergic receptor antagonists and use thereas
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury

Also Published As

Publication number Publication date
EP0633781A1 (fr) 1995-01-18
EP0633781A4 (fr) 1995-04-19
NZ251658A (en) 1996-08-27
MX9301939A (es) 1994-08-31
AU668157B2 (en) 1996-04-26
AU3945193A (en) 1993-11-08
WO1993019758A1 (fr) 1993-10-14
KR950700746A (ko) 1995-02-20
CA2133440A1 (fr) 1993-10-14

Similar Documents

Publication Publication Date Title
CA2237582C (fr) Utilisation d'antagonistes du recepteur de 5ht4 pour lutter contre les effets gastro-intestinaux d'inhibiteurs de reabsorption de la serotonine
TW200427450A (en) Pharmaceutical composition comprising histamine H3 receptor antagonist providing nasal decongestant effect
JP6762312B2 (ja) 過剰な体脂肪の治療処置または美容処置のためのｎｋ−３受容体拮抗薬
US6169098B1 (en) Composition and methods employing it for the treatment of 5-HT-mediated disorders
CN103025332A (zh) 治疗代谢综合征、2型糖尿病、肥胖或前驱糖尿病的治疗剂
JPH11510477A (ja) 消化管障害治療用の光学的に純粋な（−）ノルシサプリド
AU2008233232A1 (en) Combination therapy for the treatment-of lower urinary tract symptoms
US20240074993A1 (en) Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder
CN103282035A (zh) 治疗代谢综合征、2型糖尿病、肥胖或前驱糖尿病的治疗剂
EP2683245B1 (fr) Procédés et compositions destinés au traitement de la dépression en utilisant de la cyclobenzaprine
TWI228040B (en) Pharmaceutical compositions comprising tramadol
JPH07505398A (ja) 良性前立腺肥大症の治療用組成物および方法
JP5925862B2 (ja) セロトニン受容体介在状態を治療する方法及び組成物
JPWO2004026296A1 (ja) 抗ストレス性疾患組成物
MX2010006520A (es) Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
JP2008189616A (ja) 注意欠陥多動性障害の治療薬
JP2610735B2 (ja) 抗鬱剤および抗ストレス剤組成物
WO2003097065A1 (fr) Antagonistes du recepteur 5-ht4 utilises pour le traitement de l'insuffisance cardiaque
CN1905882A (zh) 血管内膜增厚抑制剂
Sica Centrally acting antihypertensive agents in the treatment of hypertension
JP2009234946A (ja) 併用医薬
ZA200101946B (en) A new composition.
WO2011000562A1 (fr) Eltoprazine pour le traitement de certains troubles du mouvement
HK1097752A (en) Methods for preventing antipsychotic-induced weight gain
HK1106694A (en) Methods for preventing antipsychotic-induced weight gain